[go: up one dir, main page]

BR112023021851A2 - Estimulantes de sgc - Google Patents

Estimulantes de sgc

Info

Publication number
BR112023021851A2
BR112023021851A2 BR112023021851A BR112023021851A BR112023021851A2 BR 112023021851 A2 BR112023021851 A2 BR 112023021851A2 BR 112023021851 A BR112023021851 A BR 112023021851A BR 112023021851 A BR112023021851 A BR 112023021851A BR 112023021851 A2 BR112023021851 A2 BR 112023021851A2
Authority
BR
Brazil
Prior art keywords
sgc
stimulants
concentration
pharmaceutically acceptable
increase
Prior art date
Application number
BR112023021851A
Other languages
English (en)
Inventor
Timothy Claude Barden
Rajesh R Iyengar
Iyer Karthik
Jia Lei
Jung Joon
Thomas Wai-Ho Lee
Mermerian Ara
Paul Allan Renhowe
Glen Robert Rennie
Original Assignee
Tisento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tisento Therapeutics Inc filed Critical Tisento Therapeutics Inc
Publication of BR112023021851A2 publication Critical patent/BR112023021851A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

estimulantes de sgc. a presente descrição refere-se a estimulantes de guanilato ciclase solúvel (sgc), a sais farmaceuticamente aceitáveis destes e a formulações farmacêuticas os compreendendo e a seus usos, separadamente ou em combinação com um ou mais agentes adicionais, para o tratamento de várias doenças, onde um aumento na concentração de óxido nítrico (no) e/ou um aumento na concentração de guanosina monofosfato (cgmp), ou ambos, ou uma suprarregulação da rota de no é desejável. em algumas realizações, os compostos são aqueles da tabela i ou um sal farmaceuticamente aceitável dos mesmos.
BR112023021851A 2021-04-20 2022-04-19 Estimulantes de sgc BR112023021851A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163177020P 2021-04-20 2021-04-20
US202163229248P 2021-08-04 2021-08-04
PCT/US2022/025310 WO2022225903A1 (en) 2021-04-20 2022-04-19 Sgc stimulators

Publications (1)

Publication Number Publication Date
BR112023021851A2 true BR112023021851A2 (pt) 2024-02-06

Family

ID=81579984

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023021851A BR112023021851A2 (pt) 2021-04-20 2022-04-19 Estimulantes de sgc

Country Status (15)

Country Link
US (1) US20240208979A1 (pt)
EP (1) EP4326722A1 (pt)
JP (1) JP2024515119A (pt)
KR (1) KR20240058047A (pt)
AU (1) AU2022261862A1 (pt)
BR (1) BR112023021851A2 (pt)
CA (1) CA3216127A1 (pt)
CL (1) CL2023003105A1 (pt)
CO (1) CO2023015528A2 (pt)
CR (1) CR20230532A (pt)
IL (1) IL307865A (pt)
MX (1) MX2023012398A (pt)
PE (1) PE20250267A1 (pt)
TW (1) TW202309038A (pt)
WO (1) WO2022225903A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024086179A1 (en) * 2022-10-18 2024-04-25 Tisento Therapeutics, Inc. Pyrimidine sgc stimulators
WO2024086182A1 (en) * 2022-10-18 2024-04-25 Tisento Therapeutics Inc. Treatment of mitochondrial diseases with sgc stimulators

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2928079B2 (ja) 1994-02-14 1999-07-28 永信薬品工業股▲ふん▼有限公司 １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE19830430A1 (de) 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
ES2251200T3 (es) 1998-07-08 2006-04-16 Sanofi-Aventis Deutschland Gmbh N-arilamidas del acido sulfonilaminocarboxilico sustituidas con azufre, su uso y preparaciones farmaceuticas que las comprenden.
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10216145A1 (de) 2002-04-12 2003-10-23 Bayer Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2009032249A1 (en) 2007-09-06 2009-03-12 Merck & Co., Inc. Soluble guanylate cyclase activators
EP2244575B1 (en) 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
AU2009322836B2 (en) 2008-11-25 2013-04-04 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
RU2011138970A (ru) 2009-02-26 2013-04-10 Мерк Шарп Энд Домэ Корп. Активаторы растворимой гуанилатциклазы
EP2549875B1 (en) 2010-03-25 2015-05-13 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
AU2011258436B2 (en) 2010-05-27 2014-06-12 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
US8895583B2 (en) 2010-10-28 2014-11-25 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP3152214B1 (en) 2014-06-04 2020-01-29 Merck Sharp & Dohme Corp. Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
EP3310782B1 (en) * 2015-05-28 2021-12-01 Merck Sharp & Dohme Corp. Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
WO2017197555A1 (en) 2016-05-16 2017-11-23 Merck Sharp & Dohme Corp. Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
PH12019500461B1 (en) 2016-09-02 2023-08-09 Tisento Therapeutics Inc Fused bicyclic sgc stimulators
EP3727388A1 (en) 2017-12-19 2020-10-28 Cyclerion Therapeutics, Inc. Sgc stimulators

Also Published As

Publication number Publication date
TW202309038A (zh) 2023-03-01
CO2023015528A2 (es) 2024-02-26
CA3216127A1 (en) 2022-10-27
CR20230532A (es) 2024-03-22
US20240208979A1 (en) 2024-06-27
WO2022225903A1 (en) 2022-10-27
IL307865A (en) 2023-12-01
PE20250267A1 (es) 2025-01-29
AU2022261862A1 (en) 2023-11-30
CL2023003105A1 (es) 2024-03-22
EP4326722A1 (en) 2024-02-28
AU2022261862A2 (en) 2024-07-18
KR20240058047A (ko) 2024-05-03
MX2023012398A (es) 2024-03-13
JP2024515119A (ja) 2024-04-04

Similar Documents

Publication Publication Date Title
BR112019004468A2 (pt) estimulantes de sgc
BR112023021851A2 (pt) Estimulantes de sgc
BR112021023825A2 (pt) Inibidores heterobicíclicos de mat2a e métodos de uso para tratamento de câncer
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112018004175B8 (pt) Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
WO2018089328A8 (en) TREATMENT OF CNS DISEASES USING GCS STIMULATORS
EA202091502A1 (ru) СТИМУЛЯТОРЫ sGC
BR112015025766A2 (pt) derivado de nucleosídeo altamente ativo para o tratamento de hcv
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
CO6531469A2 (es) Derivados de purina o deazapurina utiles para el tratamiento de (entre otros) infecciones virales
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
ES2656913T3 (es) Endrogenina A y agentes antineoplásicos para el tratamiento de tumores quimiosensibles o quimiorresistentes
Häussinger Osmoregulation of liver cell function: signalling, osmolytes and cell heterogeneity
BR112015018144A8 (pt) composição de emulsão água/óleo farmacêutica estável com gotículas de óleo manométricas, método para fazer a mesma e alta dose única de clopidogrel usada para tratar um paciente
Vanattou-Saïfoudine et al. A role for adenosine A1 receptor blockade in the ability of caffeine to promote MDMA “Ecstasy”-induced striatal dopamine release
MX2024010596A (es) Composiciones que comprenden 5-metoxi-2-aminoindano (meai) y n-aciletanolaminas y usos de las mismas
Dass Brief review of N-acetylcysteine as antiviral agent: potential application in COVID-19
BR112017000052A2 (pt) solução cardioplégica de uso geral (variantes)
BR112023019460A2 (pt) Composto, antagonista do receptor de endotelina a e composição farmacêutica que compreendem o mesmo e usos do composto como terapia e na produção de um antagonista do receptor de endotelina a
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
성우이 et al. Antidotes of cyanide intoxication
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
Deree et al. The effects of a novel resuscitation strategy combining pentoxifylline and hypertonic saline on neutrophil MAPK signaling
AR125378A1 (es) Estimuladores de guanilil ciclasa soluble (sgc)